Retinal organoids are becoming a powerful tool in the process of drug discovery, as recently shown by researchers at Newcells Biotech and Newcastle University in a study led by Professor Majlinda Lako
Newcells Biotech has announced that Dr Colin Brown, one of the world’s leading experts on drug transport and drug toxicity in kidney will join the company as Director of ADMET Technology. The company has also
Dr Colin Brown will be presenting two posters at 22nd North American Meeting of the International Society for the Study of Xenobiotics.
Newcells Biotech has secured a £2 million investment from NVM Private Equity and Northstar Ventures to support its ambitious growth plans.
As the NHS marks its 70th birthday, the BBC explores the genetic advances changing the face of medicine, including the extraordinary science that helped a blind man to see again.
Age-related macular degeneration (AMD) remains the commonest cause of blindness in the developed world. This review article by Dr Valeria Chichagova and Dr Dean Hallam provides an overview of progress made, ongoing studies and challenges ahead.
If you are attending the World Preclinical Congress and would like to arrange a meeting with Dr Colin Brown, then please let us know.
Dr Valeria Chichagova will be presenting at the inaugural Faculty of Medical Science (FMS) Post-Doc Symposium on Friday 15th June 2018.
This year’s British Toxicology Society Congress 2018 saw the IVTS Poster Prize awarded to our own Dr Valeria Chichagova, for her work in human retina models.
The Newcells Biotech team will be attending the British Toxicological Society Annual Congress 2018 that is taking place in Gateshead on 16th-18th April.
Newcells Biotech in partnership with Newcastle University has been awarded further funding from the NC3R CRACK IT project to create 3D retinal organoids that more closely recapitulate the structure and function of the human retina.
Current cell assays for in vitro screening are based on genetically modified cell lines which are crude models of human biology.